BPC-157 — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

BPC-157 Dosing Guide: Protocol, Reconstitution & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols BPC-157 Dosing Guide: Protocol, Reconstitution & Safety (2026) Protocol / Research Dosing Guide BPC-157 Dosing Guide: Protocol, Reconstitution & Safety (2026) An evidence-based BPC-157 protocol guide covering dosing ranges, reconstitution math, oral vs injectable use, cycle length, and safety considerations for gut and tissue repair research. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners BPC-157 Supply View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status BPC-157 Comparisons Related Protocols Blood Tests FAQ References BPC-157 Quick Start BPC-157 stands for Body Protection Compound 157. It is a synthetic 15-amino-acid peptide derived from a sequence first identified in human gastric juice in the 1990s.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (10) · phenotypes (0)

evidence_reference, dosing_reference, safety_reference, mechanism, monitoring_reference

Findings (139) · awaiting review (101)

regulatory · pending

WADA bans substances that lack regulatory approval

regulatory · pending

Format note Capsule products are commercial supplements, not FDA-approved drugs.

outcome · pending

They are not predictions of personal outcomes.

dosing · pending

Evidence boundary BPC-157 has no published human Phase 2 or Phase 3 dose-finding trial.

dosing · pending

Published preclinical work used a wide range of oral doses; community-derived planning often references ~250-500 mcg once or twice daily.

dosing · pending

Direct human oral dose-finding trials are limited.

dosing · pending

This is not a dosing recommendation.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners BPC-157 Supply View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status BPC-157 Comparisons Related Protocols Blood Tests FAQ References BPC-157 Quick Start BPC-157 stands for Body Protection Compound 157.

dosing · pending

The most common is subcutaneous injection from a reconstituted vial.

dosing · pending

Schedule shape Typical published research planning splits a daily total into one or two doses.

regulatory · pending

Research status Mostly preclinical evidence; not FDA-approved as of June 2026.

dosing · pending

Use this page for dose steps, vial mixing, timing, and supplies.

safety · pending

For the bigger research picture, read the BPC-157 research guide on how it works, key studies, safety notes, and common comparisons.

dosing · pending

BPC-157 Dosing Protocol & Schedule BPC-157 has been studied in two main research formats.

dosing · pending

Subcutaneous injection is the most commonly referenced research format.

dosing · pending

(Frontiers in Pharmacology, 2022) reports a half-life under 30 minutes after IM or IV administration in rodent and dog models, which is why split-dose schedules appear in the literature.

dosing · pending

Common research-planning ranges (subcutaneous) Planning band Low Per-dose range ~250 mcg Frequency Once daily Typical context Maintenance / general research planning Planning band Standard Per-dose range ~250 mcg Frequency Twice daily Typical context Most published preclinical protocols and community references Planning band High Per-dose range ~500 mcg Frequency Twice daily Typical context Short-term acute-injury research planning Planning band Per-dose range Frequency Typical context Low ~250 mcg Once daily Maintenance / general research planning Standard ~250 mcg Twice daily Most published preclinical protocols and community references High ~500 mcg Twice daily Short-term acute-injury research planning These ranges reflect community-derived research planning.

dosing · pending

Direct human dose-finding trials are limited; a 2025 IV pilot in two adults used 10 mg and 20 mg single infusions and reported no adverse effects (Lee et al., Alternative Therapies in Health and Medicine).

dosing · pending

This is not a dosing recommendation.

dosing · pending

Oral research-planning ranges are usually higher than the subcutaneous ranges to account for lower absorption across the gut lining.

dosing · pending

The numbers below assume the standard research-planning band of about 250 mcg twice daily from 10 mg vials reconstituted with 2 mL bacteriostatic water.

dosing · pending

Peptide Vials Math assumes 10 mg vials reconstituted with 2 mL BAC water (concentration 5,000 mcg/mL).

dosing · pending

At 250 mcg twice daily, one 10 mg vial covers roughly 20 days.

dosing · pending

Cycle length Planning note 4 weeks 2 x 10 mg vials 56 doses needed at 250 mcg 2x/day; round up for priming losses.

dosing · pending

6-8 weeks 3 x 10 mg vials 6 wee

dosing · pending

ks: 84 doses needed; three vials cover 120 doses before losses.; 8 weeks: 112 doses needed; three vials gives a small margin.

dosing · pending

12 weeks 5 x 10 mg vials 168 doses needed; build in margin for storage limits.

dosing · pending

4 weeks 2 x 10 mg vials 56 doses needed at 250 mcg 2x/day; round up for priming losses.

dosing · pending

6-8 weeks 3 x 10 mg vials 6 weeks: 84 doses needed; three vials cover 120 doses before losses.; 8 weeks: 112 doses needed; three vials gives a small margin.

dosing · pending

Insulin Syringes (U-100) Use 0.3 mL / 30-unit syringes for small daily draws.

dosing · pending

At 5,000 mcg/mL, 250 mcg = 0.05 mL = 5 units.

dosing · pending

Bacteriostatic Water 2 mL BAC water per vial.

dosing · pending

10 mL bottles are standard; once opened, follow supplier beyond-use guidance.

dosing · pending

Cycle length Planning note 4-12 weeks 1 x 10 mL bottle 4 weeks: 2 vials use 4 mL total; one bottle gives margin.; 6 weeks: 3 vials us

dosing · pending

e 6 mL total; one bottle gives margin.; 8 weeks: 3 vials use 6 mL total; one bottle gives margin.; 12 weeks: 5 vials use 10 mL total.

dosing · pending

4-12 weeks 1 x 10 mL bottle 4 weeks: 2 vials use 4 mL total; one bottle gives margin.; 6 weeks: 3 vials use 6 mL total; one bottle gives margin.; 8 weeks: 3 vials use 6 mL total; one bottle gives margin.; 12 weeks: 5 vials use 10 mL total.

dosing · pending

Math assumes 10 mg vials reconstituted with 2 mL BAC water unless otherwise noted.

dosing · pending

The amount of BAC water added sets the final concentration, which sets the draw volume per dose.

mechanism · pending

Animal evidence is much larger and has been the basis for almost all of the published mechanism work.

Processing

Processed into 25 searchable sections.